Enhanced Topical Compositions for Hair Growth and Alopecia Treatment
Legal Citation
Summary of the Inventive Concept
The present inventive concept relates to improved topical compositions and methods for stimulating hair growth, treating androgenic alopecia, and preventing hair loss, addressing the limitations of existing dutasteride-based formulations.
Background and Problem Solved
The original patent disclosed topical compositions comprising dutasteride for hair growth and alopecia treatment. However, these compositions have limitations, such as poor solubility, permeability, and potential side effects. The new inventive concept addresses these limitations by introducing dutasteride derivatives, hydrophilic and lipophilic excipients, penetration enhancers, antioxidants, chelating agents, and viscosity modifying agents to create more efficient and safer formulations.
Detailed Description of the Inventive Concept
The new inventive concept comprises four main aspects: (1) a topical composition with a dutasteride derivative exhibiting improved solubility and permeability, (2) a method for treating androgenic alopecia with a formulation reducing the risk of hyposexuality and ejaculation decrease, (3) a system for delivering dutasteride to the scalp with minimized side effects, and (4) a topical composition for preventing hair loss with maintained efficacy and reduced risk of side effects. These aspects are achieved through the strategic combination of excipients, penetration enhancers, antioxidants, and other agents.
Novelty and Inventive Step
The new inventive concept's novelty lies in the introduction of dutasteride derivatives, specific excipient combinations, and the optimized formulations that address the limitations of the original patent. The inventive step is the unexpected improvement in solubility, permeability, and safety profiles achieved through these combinations.
Alternative Embodiments and Variations
Alternative embodiments may include varying the concentration of dutasteride derivatives, using different hydrophilic and lipophilic excipients, or incorporating additional agents to enhance efficacy and safety. Variations may also include different application forms, such as gels, creams, or shampoos, to expand the range of treatment options.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the hair care and pharmaceutical industries, offering improved treatment options for androgenic alopecia and hair loss. The target market includes individuals suffering from hair loss and alopecia, as well as dermatologists and healthcare professionals seeking more effective and safer treatment options.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations, specifically topical compositions for hair loss treatment involving 5α-reductase inhibitors like dutasteride, requiring expertise in pharmaceutical chemistry, drug delivery systems, and dermatological formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical formulation scientist with advanced degree (MS/PhD) in pharmaceutical sciences, expertise in drug delivery, knowledge of excipient interactions, understanding of topical drug formulation strategies, and familiarity with hair loss treatment technologies
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable modifications to the source patent's dutasteride topical composition by systematically adjusting excipient ratios, incorporating penetration enhancers, and optimizing delivery mechanisms. The core therapeutic agent remains dutasteride, with incremental improvements in formulation that would be considered routine optimization within pharmaceutical development. These variations demonstrate standard pharmaceutical engineering approaches to enhancing drug delivery and minimizing side effects.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,556 |
|---|---|
| Title | Topical compositions of dutasteride |
| Assignee(s) | SHILPA MEDICARE LIMITED |